HUNTERTUTORING

Standard syllabus

Medicinal chemistry · Graduate · Chemistry

Topics

Drug design principles

  • Structure-based drug design (SBDD) workflow
  • Ligand-based drug design and pharmacophore modeling
  • Fragment-based drug discovery (FBDD)
  • Bioisosteres and scaffold hopping
  • Privileged structures and drug-like scaffolds
  • Conformational restriction and preorganization
  • Prodrug design and targeted delivery strategies
  • Salt and polymorph selection for development
  • Intellectual property strategy in medicinal chemistry
  • Target validation and druggability assessment

ADMET optimization

  • Lipophilicity, solubility, and permeability balance
  • Caco-2 and PAMPA permeability models
  • Blood-brain barrier penetration prediction
  • Cytochrome P450 inhibition and induction
  • Reactive metabolites and bioactivation toxicity
  • hERG channel liability and cardiac safety
  • Plasma protein binding and free drug hypothesis
  • Metabolic stability assays: microsomal, hepatocyte
  • PK/PD modeling for dose selection (introduction)
  • Formulation chemistry for oral, IV, and topical delivery

Synthetic medicinal chemistry

  • Scale-up considerations for drug candidates
  • Process route scouting and patent avoidance
  • Asymmetric synthesis for enantiopure drugs
  • Late-stage functionalization in drug optimization
  • Parallel synthesis and SAR library generation
  • High-throughput chemistry and automation
  • Green chemistry metrics in pharmaceutical manufacturing
  • Impurity profiling and specification setting
  • Solid-form screening: salts, cocrystals, amorphous dispersions
  • GMP synthesis and regulatory chemistry requirements

Therapeutic areas and case studies

  • Oncology: kinase inhibitors, immunotherapies, ADCs
  • CNS drugs: blood-brain barrier, receptor selectivity
  • Antibiotics and antimicrobial resistance
  • Antiviral drug design: protease and polymerase inhibitors
  • Cardiovascular and metabolic disease targets
  • Anti-inflammatory and immunomodulatory drugs
  • Rare disease and orphan drug programs
  • Biologics vs small molecules: decision frameworks
  • Failed drugs and lessons from clinical setbacks
  • FDA approval pathways: NDA, ANDA, BLA (overview)

Pricing

Graduate-level rates are set on consultation. See the pricing page for K–12 and undergraduate rates.